PDB46 - Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data

I Daacke,P Kandaswamy,A Tebboth,A Kansal,O Reifsnider

doi:10.1016/j.jval.2016.09.1876

PDB46 - Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data

I Daacke, P Kandaswamy + Show 3 more

Open Access

https://doi.org/10.1016/j.jval.2016.09.1876

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Oct 31, 2016
Citations: 11	License type: publisher-specific-oa

Affiliation: Boehringer Ingelheim (United Kingdom), Boehringer Ingelheim (Germany), Ithaka Harbors

#Cost-Effectiveness Of Empagliflozin #Type 2 Diabetes Mellitus + Show 3 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PDB46 - Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data

Full Text